Ferric carboxymaltose versus ferric gluconate in hemodialysis patients: Reduction of erythropoietin dose in 4 years of follow-up

• Главные авторы: Antonio Lacquaniti (Автор), Patrizio Pasqualetti (Автор), Teresa Casuscelli di Tocco (Автор), Susanna Campo (Автор), Stefania Rovito (Автор), Maurizio Bucca (Автор), Antonino Ragusa (Автор), Paolo Monardo (Автор)
• Формат: ‌
• Опубликовано: The Korean Society of Nephrology, 2020-09-01T00:00:00Z.
• Предметы: article
• Online-ссылка: Connect to this object online.

Background : : Ferric carboxymaltose (FCM) is a parenteral, dextran-free iron formulation designed to overcome the limitations of existing iron preparations. The main aim of this study was to retrospectively examine results obtained from a long period of FCM therapy in hemodialysis patients who have...